Actively building life science companies

5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors.

Scroll to experience 5AM Ventures

Supporting companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science.

Read Me

Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting
Read Me

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH)
Read Me

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an “Off-The-Shelf” Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
Read Me

Portal Announces 2nd Major Pharma Partnership with LEO Pharma
Read Me

Homology Medicines Announces Appointment of Gabriel M. Cohn, MD, as Chief Medical Officer

Pushing the healthcare industry forward

$ 0 B

UNDER MANAGEMENT

We’re a life science venture capital firm founded in 2002 and currently investing $350M from 5AM Ventures VI and $147M from 5AM Opportunities I.
0

PORTFOLIO COMPANIES

Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
0

ONGOING CLINICAL TRIALS

Our portfolio companies currently have over 18,000 patients enrolled across 750 test sites in ongoing clinical trials.

San Francisco, CA

Boston, MA